无创血管血流储备分数与血流储备分数指导中等冠状动脉狭窄血运重建的比较(LIPSIA-STRATEGY)试验:随机对照试验研究方案
LIPSIA-STRATEGY是一项由研究者发起的多中心、开放标签、随机对照试验,计划纳入1054例稳定型心绞痛或急性冠脉综合征(ACS)伴中等冠状动脉狭窄的患者,1:1随机分配至基于血管造影衍生的血管血流储备分数(vFFR)或基于压力导丝测量的血流储备分数(FFR)指导血运重建。主要终点为随机化后第一年内主要不良心血管事件(MACE)的发生。该试验将是首个比较血管造影衍生vFFR与有创FFR对临床结局影响的随机研究。
要点
- LIPSIA-STRATEGY为首个比较血管造影衍生vFFR与有创FFR指导中等冠脉狭窄血运重建临床结局的随机对照试验。
- 计划纳入1054例稳定型心绞痛或ACS患者,ACS患者仅纳入非罪犯血管。
- 主要终点为随机化后1年内MACE发生,采用1:1随机、多中心、开放标签设计。
核心结论
- LIPSIA-STRATEGY试验将首次在有中等冠状动脉病变的患者中比较血管造影衍生vFFR与有创FFR指导血运重建的临床结局。
研究设计与样本
- 多中心、随机对照、研究者发起、开放标签研究,计划纳入1054例患者,1:1随机分配至vFFR指导组或FFR指导组。
- 主要纳入标准为稳定型心绞痛或ACS背景下,肉眼评估存在一个或多个原生主要心外膜冠状动脉的中等狭窄;ACS患者仅考虑非罪犯血管。
关键数值与推荐
- 主要终点为随机化后第一年内主要不良心血管事件(MACE)的发生。
- 试验注册号:ClinicalTrials.gov NCT03497637,注册日期2018-04-13。
临床怎么用
- 若试验证实血管造影衍生vFFR与有创FFR临床结局相当,可能为中等冠脉狭窄的功能学评估提供无需压力导丝、缩短手术时间的替代方案。
局限性
- 研究方案未报告样本量计算依据、具体MACE定义、随访时长细节及盲法实施方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines on coronary revascularization support the use of wire-based coronary physiology measurements to guide decision making in patients with coronary artery stenoses. Nevertheless, the use of these techniques in clinical practice is variable and its application worldwide remains limited by its requirement for the use of an intracoronary pressure wire and prolonged procedure time. Recently, angiography-based wire-free techniques to estimate fractional flow reserve (FFR) values have been introduced. These developments may translate towards more physiology-guided intervention bearing the potential to improve clinical outcomes in patients with stable coronary artery disease (CAD). METHODS: The LIPSIA-STRATEGY trial is a randomized controlled, investigator-initiated, multicenter, open-label study. A total of 1054 eligible patients will be randomized 1:1 to coronary revascularization based on angiography-derived vessel fractional flow reserve (vFFR) or revascularization based on FFR obtained by pressure wire measurements. The major inclusion criterion is the presence of visually assessed intermediate coronary artery stenoses in one or more native major epicardial coronary arteries in the setting of stable angina or an acute coronary syndrome (ACS). In patients with an ACS, only non-culprit vessels will be considered for inclusion. The primary endpoint is the occurrence of major adverse cardiovascular events (MACE) during the first year after randomization. DISCUSSION: The LIPSIA-STRATEGY trial will be the first to compare angiography-derived vFFR with invasive FFR with respect to clinical outcomes in patients with intermediate coronary lesions. TRIAL REGISTRATION: ClinicalTrials.gov NCT03497637. Registered 2018-04-13.
引用
- Majunke N, Desch S, Kister T, et al. Non-invasive vessel fractional flow reserve versus fractional flow reserve guidance to revascularize intermediate coronary stenosis (LIPSIA-STRATEGY) trial: study protocol for a randomized controlled trial. Trials. 2026. PMID: 41923139. doi:10.1186/s13063-026-09652-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。